$10 Billion Deal, page-141

"Significant Immunological Outcomes in BIT225 HIV-1 Clinical Trial "

Can someone explain how they came to this conclusion in a short time frame after treatment based on 27 patients with half on placebo. The variability of data on such a small patient population looking at immune system ages and neurocognitive disorder is going to give you non conclusive data imo. Longer term data on over 300 patients in a phase 2b study can only give any significant results. IMO the reported results are a beat up to get the 6c options exercised.


"These include an immune system ages more quickly, and there are other problems such as HIV-associated neurocognitive disorder (also known as AIDS-related dementia).